Examkin

Soru

Zorluk: OrtaEnd-of-Life and Palliative Care

A 59-year-old woman is evaluated in the hospital for intractable nausea, vomiting, and diffuse abdominal pain. She has a history of stage IV ovarian cancer with extensive peritoneal carcinomatosis that is no longer responsive to chemotherapy. Three days ago, her oncologist discussed her prognosis, and the patient expressed a clear desire to focus exclusively on comfort care and avoid further invasive procedures. Over the past 24 hours, she has been unable to tolerate any oral intake, and her last bowel movement was four days ago. She is awake, alert, and fully oriented. She reiterates her goals of care and explicitly refuses any surgical evaluation. Her temperature is 37.1°C (98.8°F), blood pressure is 105/65 mm Hg, pulse is 110/min, and respirations are 18/min. Physical examination reveals a markedly distended, tympanic abdomen with high-pitched, tinkling bowel sounds. There is diffuse mild tenderness but no rebound or guarding. Plain radiography of the abdomen shows multiple dilated loops of small bowel with air-fluid levels and a paucity of gas in the colon. Which of the following is the most appropriate next step in the management of this patient?

  1. Subcutaneous octreotideCevap
  2. B
    Intravenous metoclopramide
  3. C
    Computed tomography of the abdomen and pelvis with oral contrast
  4. D
    Discharge home with a prescription for oral prochlorperazine
  5. E
    Request a psychiatric consultation to evaluate the patient's competence to refuse surgery

Cevap

The most appropriate next step in management is the administration of subcutaneous octreotide.
The correct answer is subcutaneous octreotide because it effectively reduces gastrointestinal secretions, pancreatic secretions, and splanchnic blood flow. In a patient with an inoperable malignant bowel obstruction who desires comfort care, octreotide significantly decreases intraluminal volume and pressure, thereby alleviating intractable vomiting and severe abdominal distension without the need for surgical intervention.

Adım Adım Çözüm

1
Identify the clinical syndrome based on the presentation and imaging.
The patient has intractable vomiting, a distended tympanic abdomen, obstipation, and air-fluid levels on radiography, which are classic signs of a malignant bowel obstruction (MBO).
Recognizing the underlying pathology is necessary to select targeted pharmacologic therapies.
2
Determine the appropriate goals of care based on the patient's preferences.
The patient has decision-making capacity and has explicitly requested a comfort-focused approach, refusing further invasive or surgical procedures.
Patient autonomy dictates that management must align with her expressed desire to avoid invasive interventions.
3
Select the most appropriate medical intervention to alleviate the specific symptoms of MBO.
Subcutaneous octreotide is chosen to manage the obstruction medically.
Octreotide, a somatostatin analog, decreases gastrointestinal secretions and motility, which effectively reduces intraluminal pressure, abdominal distension, and vomiting in inoperable MBO.

Anahtar Kavram

The medical management of malignant bowel obstruction in palliative care focuses on symptom control using anti-secretory agents (such as octreotide), antiemetics, and analgesics, while strictly honoring the patient's goals of care and avoiding invasive procedures if comfort is the primary objective.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru